What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
His main research concerns Surgery, Pulmonary embolism, Internal medicine, Thrombosis and Anesthesia.
His works in Low molecular weight heparin, Deep vein, Venous thrombosis, Randomized controlled trial and Venography are all subjects of inquiry into Surgery.
His study in Pulmonary embolism is interdisciplinary in nature, drawing from both Respiratory disease, Embolism, Thrombolysis, Intensive care medicine and First episode.
He frequently studies issues relating to Cardiology and Internal medicine.
His studies examine the connections between Thrombosis and genetics, as well as such issues in Warfarin, with regards to Aspirin.
His study on Anesthesia also encompasses disciplines like
- Knee replacement together with Discovery and development of direct thrombin inhibitors, Ximelagatran and Direct thrombin inhibitor,
- Rivaroxaban which intersects with area such as Vitamin K antagonist.
His most cited work include:
- Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) (2467 citations)
- Oral rivaroxaban for symptomatic venous thromboembolism (2257 citations)
- Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (1720 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Surgery, Pulmonary embolism, Thrombosis and Cardiology.
His Stroke, Prospective cohort study, Atrial fibrillation and Cancer study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines.
His research investigates the connection between Surgery and topics such as Anesthesia that intersect with issues in Discovery and development of direct thrombin inhibitors.
His Pulmonary embolism research is multidisciplinary, relying on both Incidence, Confidence interval, Meta-analysis, Intensive care medicine and Radiology.
His research integrates issues of Venous thromboembolism, Clinical trial and Antithrombotic in his study of Intensive care medicine.
His Thrombosis research includes themes of Asymptomatic and Vein.
He most often published in these fields:
- Internal medicine (43.00%)
- Surgery (30.17%)
- Pulmonary embolism (24.64%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (43.00%)
- Atrial fibrillation (10.20%)
- Pulmonary embolism (24.64%)
In recent papers he was focusing on the following fields of study:
Giancarlo Agnelli mainly focuses on Internal medicine, Atrial fibrillation, Pulmonary embolism, Cardiology and Intensive care medicine.
In the field of Internal medicine, his study on Stroke, Prospective cohort study, Cancer and Venous thromboembolism overlaps with subjects such as In patient.
His Pulmonary embolism research is multidisciplinary, incorporating elements of Randomized controlled trial, Thrombosis, Venous thrombosis, Deep vein and Apixaban.
His Thrombosis study is concerned with Surgery in general.
In the subject of general Cardiology, his work in Stenosis is often linked to Risk assessment, thereby combining diverse domains of study.
His Intensive care medicine research incorporates elements of Low molecular weight heparin, Health related quality of life, Clinical trial and Antithrombotic.
Between 2015 and 2021, his most popular works were:
- Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer (167 citations)
- Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function (122 citations)
- Guidance for the treatment of deep vein thrombosis and pulmonary embolism (120 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Cancer
His scientific interests lie mostly in Internal medicine, Pulmonary embolism, Cardiology, Stroke and Atrial fibrillation.
His work in the fields of Internal medicine, such as Prospective cohort study, Cancer, Odds ratio and Warfarin, overlaps with other areas such as In patient.
His Pulmonary embolism research includes elements of Randomized controlled trial, Thrombosis, Venous thrombosis, Deep vein and Intensive care medicine.
His work deals with themes such as Meta-analysis and Apixaban, which intersect with Randomized controlled trial.
His Venous thrombosis study improves the overall literature in Surgery.
His Cardiology study combines topics from a wide range of disciplines, such as Hematology and Severity of illness.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
